Mkts

Metagenomi Therapeutics, Inc.

NASDAQ: MGX
$0.63+0.00 (+0.13%)
As of Nov 18, 9:30 AM ET

Key statistics

Day range
0.620.69
52-week range
0.601.87
Today
Open0.63
Previous close0.63
Volume86.6K
Valuation
Market cap26.80M
P/E ratio—
EPS (TTM)-2.30
Income & risk
Dividend / yield—
Beta0.81
Avg volume216.6K
Discussion

MGX News

Stories mentioning MGX from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue1,2483,9118,6598,5134,1279,61411,51420,008
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development19,30021,50125,28322,50725,14223,16426,25628,320
Sales General & Admin
Total Operating Expenses25,83528,27831,49829,50031,94730,23733,89736,871
Operating Income (Loss)(24,587)(24,367)(22,839)(20,987)(27,820)(20,623)(22,383)(16,863)
Interest Income1,5391,8842,2142,4852,8873,1963,6163,976
Interest Expense
Other Expense(1.00)(11.00)(2.00)(70.00)(8.00)(49.00)(57.00)(51.00)
Pretax Income(23,049)(22,494)(20,627)(19,864)(24,941)(24,606)(20,879)(12,938)
Tax Provision10.0034.00(234.00)44.0098.00(1,208)(2,106)(2,199)
Net Income (Loss)(23,059)(22,528)(20,393)(19,908)(25,039)(23,398)(18,773)(10,739)
Earnings Per Share (Basic)(0.61)(0.60)(0.55)(0.54)(0.68)(0.71)(0.51)(0.29)
Earnings Per Share (Diluted)(0.61)(0.60)(0.55)(0.54)(0.68)(0.71)(0.51)(0.29)
Weighted Average Shares Outstanding (Basic)37,58137,25137,34937,15737,01933,02836,76636,625
Weighted Average Shares Outstanding (Diluted)37,58137,25137,34937,15737,01933,02836,76636,625

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About MGX

Metagenomi Therapeutics, Inc. (NASDAQ: MGX) is a stock listed on the Nasdaq Stock Market under the ticker symbol MGX. It last traded at $0.6300 (Nov 18, 2026, 9:30 AM ET), up 0.1% on the day. That gives Metagenomi Therapeutics a market capitalisation of $26.8M.

Over the past 52 weeks MGX has traded between $0.6000 and $1.87.

Revenue for the quarter ended Mar 31, 2026 was $1.2M; a net loss of $23.1M. Revenue was down 69.8% from $4.1M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$1.2M-$23.1M-1847.7%
Dec 31, 2025$3.9M-$22.5M-576.0%
Sep 30, 2025$8.7M-$20.4M-235.5%
Jun 30, 2025$8.5M-$19.9M-233.9%

From Metagenomi Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…